TEDUGLUTIDE

Summary

Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue approved to augment intestinal adaptation in short bowel syndrome with intestinal failure (SBS-IF) ^[3]. In a phase III randomized controlled trial, 24 weeks of teduglutide significantly increased the proportion of patients achieving a one-day-or-more reduction in weekly parenteral support need versus placebo (54% vs 23%), raised plasma citrulline as a biomarker of mucosal mass, and was generally well tolerated ^[2]. It is the first successful pharmacological intervention to enhance intestinal adaptation in SBS and has since been approved for pediatric patients over one year of age ^[3], with health-technology guidance issued for its use ^[4]. As a large, poorly orally absorbed protein, milk transfer and infant exposure during breastfeeding are expected to be minimal ^[1]. The evidence base of randomized trials plus regulatory approval supports strong, established clinical efficacy in its indicated population.

Sources

1. 1. Teduglutide Drugs and Lactation Database (LactMed), 2006.
2. 2. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure Gastroenterology, 2012.
3. 3. Teduglutide for pediatric short bowel syndrome patients Expert review of gastroenterology & hepatology, 2021.
4. 4. Teduglutide for treating short bowel syndrome (NICE Technology Appraisal) National Institute for Health and Care Excellence (NICE), 2022.

For educational purposes only.